share_log

Agios Pharmaceuticals Analyst Ratings

Agios Pharmaceuticals Analyst Ratings

Agios 製藥分析師評級
Benzinga ·  2023/08/07 11:42
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/07/2023 24.32% JP Morgan $33 → $32 Maintains Neutral
06/27/2023 63.17% RBC Capital $40 → $42 Maintains Outperform
02/03/2023 59.29% Piper Sandler → $41 Initiates Coverage On → Overweight
12/01/2022 28.21% JP Morgan $48 → $33 Maintains Neutral
11/17/2022 24.32% Goldman Sachs $17 → $32 Upgrades Sell → Neutral
08/05/2022 43.75% SVB Leerink $33 → $37 Maintains Outperform
07/27/2022 28.21% SVB Leerink → $33 Upgrades Market Perform → Outperform
05/24/2022 -37.84% Goldman Sachs $20 → $16 Maintains Sell
05/17/2022 28.21% SVB Leerink $30 → $33 Maintains Market Perform
03/07/2022 -10.64% Goldman Sachs $37 → $23 Maintains Sell
03/03/2022 272.96% HC Wainwright & Co. $98 → $96 Maintains Buy
02/25/2022 160.3% RBC Capital $61 → $67 Maintains Outperform
02/24/2022 272.96% HC Wainwright & Co. $98 → $96 Maintains Buy
02/22/2022 16.55% SVB Leerink $32 → $30 Maintains Market Perform
02/18/2022 280.73% HC Wainwright & Co. $95 → $98 Maintains Buy
02/16/2022 70.94% Canaccord Genuity $52 → $44 Maintains Buy
12/03/2021 109.79% B of A Securities → $54 Initiates Coverage On → Buy
11/18/2021 63.17% SVB Leerink $50 → $42 Maintains Market Perform
11/04/2021 269.08% HC Wainwright & Co. $93 → $95 Maintains Buy
07/30/2021 261.31% HC Wainwright & Co. $88 → $93 Maintains Buy
07/30/2021 51.52% Goldman Sachs $58 → $39 Downgrades Neutral → Sell
07/01/2021 — Raymond James Initiates Coverage On → Market Perform
06/10/2021 241.88% HC Wainwright & Co. → $88 Initiates Coverage On → Buy
04/30/2021 152.53% Canaccord Genuity $57 → $65 Maintains Buy
03/01/2021 109.79% JP Morgan → $54 Downgrades Overweight → Neutral
02/26/2021 94.25% SVB Leerink $55 → $50 Downgrades Outperform → Market Perform
01/27/2021 113.68% SVB Leerink $51 → $55 Maintains Outperform
12/28/2020 121.45% Canaccord Genuity $70 → $57 Maintains Buy
12/09/2020 136.99% SVB Leerink $67 → $61 Maintains Outperform
10/22/2020 78.71% Barclays → $46 Upgrades Equal-Weight → Overweight
10/19/2020 168.07% Needham $71 → $69 Maintains Buy
10/19/2020 171.95% Canaccord Genuity $72 → $70 Maintains Buy
10/19/2020 160.3% SVB Leerink $72 → $67 Maintains Outperform
10/19/2020 183.61% Piper Sandler $80 → $73 Maintains Overweight
07/31/2020 179.72% Cantor Fitzgerald $70 → $72 Maintains Overweight
06/15/2020 179.72% SVB Leerink $70 → $72 Maintains Outperform
06/15/2020 191.38% Citigroup $64 → $75 Maintains Buy
05/04/2020 218.57% JP Morgan $72 → $82 Maintains Overweight
03/04/2020 94.25% Barclays → $50 Initiates Coverage On → Equal-Weight
02/14/2020 171.95% Cantor Fitzgerald $64 → $70 Reiterates → Overweight
12/09/2019 90.37% BMO Capital $45 → $49 Maintains Outperform
12/04/2019 164.18% JP Morgan $80 → $68 Maintains Overweight
11/26/2019 148.64% Cantor Fitzgerald → $64 Initiates Coverage On → Overweight
11/05/2019 148.64% Citigroup $80 → $64 Maintains Buy
09/23/2019 — Guggenheim Upgrades Neutral → Buy
09/12/2019 74.83% BMO Capital → $45 Initiates Coverage On → Outperform
05/23/2019 113.68% Goldman Sachs → $55 Assumes → Neutral
02/20/2019 — Oppenheimer Assumes → Perform
02/15/2019 210.8% Leerink Swann → $80 Upgrades Market Perform → Outperform
09/25/2018 210.8% Leerink Swann → $80 Initiates Coverage On → Market Perform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
08/07/2023 24.32% 摩根大通 $33→$32 維護 中性
2023年6月27日 63.17% 加拿大皇家銀行資本 $40→$42 維護 跑贏大盤
02/03/2023 59.29% 派珀·桑德勒 →$41 開始承保 →超重
12/01/2022 28.21% 摩根大通 $48→$33 維護 中性
2022年11月17日 24.32% 高盛 $17→$32 升級 賣出→中性
08/05/2022 43.75% SVB Leerink $33→$37 維護 跑贏大盤
07/27/2022 28.21% SVB Leerink →$33 升級 市場表現優於→
2022年05月24日 -37.84% 高盛 $20→$16 維護 賣
2022/05/17 28.21% SVB Leerink $30→$33 維護 市場表現
03/07/2022 -10.64% 高盛 $37→$23 維護 賣
03/03/2022 272.96% HC Wainwright公司 $98→$96 維護 買
02/25/2022 160.3% 加拿大皇家銀行資本 $61→$67 維護 跑贏大盤
02/24/2022 272.96% HC Wainwright公司 $98→$96 維護 買
02/22/2022 16.55% SVB Leerink $32→$30 維護 市場表現
02/18/2022 280.73% HC Wainwright公司 $95→$98 維護 買
02/16/2022 70.94% 卡納科特·格納奇 $52→$44 維護 買
12/03/2021 109.79% B of A證券 →$54 開始承保 →購買
2021年11月18日 63.17% SVB Leerink $50→$42 維護 市場表現
11/04/2021 269.08% HC Wainwright公司 $93→$95 維護 買
07/30/2021 261.31% HC Wainwright公司 $88→$93 維護 買
07/30/2021 51.52% 高盛 $58→$39 評級下調 中性→銷售
07/01/2021 - 雷蒙德·詹姆斯 開始承保 →市場表現
2021/10/06 241.88% HC Wainwright公司 →$88 開始承保 →購買
04/30/2021 152.53% 卡納科特·格納奇 $57→$65 維護 買
03/01/2021 109.79% 摩根大通 →$54 評級下調 超重→中性
02/26/2021 94.25% SVB Leerink $55→$50 評級下調 跑贏→市場表現
2021/01/27 113.68% SVB Leerink $51→$55 維護 跑贏大盤
12/28/2020 121.45% 卡納科特·格納奇 $70→$57 維護 買
12/09/2020 136.99% SVB Leerink $67→$61 維護 跑贏大盤
10/22/2020 78.71% 巴克萊 →$46 升級 等重→超重
10/19/2020 168.07% 李約瑟 $71→$69 維護 買
10/19/2020 171.95% 卡納科特·格納奇 $72→$70 維護 買
10/19/2020 160.3% SVB Leerink $72→$67 維護 跑贏大盤
10/19/2020 183.61% 派珀·桑德勒 $80→$73 維護 超重
07/31/2020 179.72% 康託·菲茨傑拉德 $70→$72 維護 超重
2020/06/15 179.72% SVB Leerink $70→$72 維護 跑贏大盤
2020/06/15 191.38% 花旗集團 $64→$75 維護 買
05/04/2020 218.57% 摩根大通 $72→$82 維護 超重
03/04/2020 94.25% 巴克萊 →$50 開始承保 →等重
02/14/2020 171.95% 康託·菲茨傑拉德 $64→$70 重申 →超重
2019年12月09日 90.37% 蒙特利爾銀行資本 $45→$49 維護 跑贏大盤
2019/12/04 164.18% 摩根大通 $80→$68 維護 超重
2019年11月26日 148.64% 康託·菲茨傑拉德 →$64 開始承保 →超重
2019年11月05日 148.64% 花旗集團 $80→$64 維護 買
2019年09月23日 - 古根海姆 升級 中性→購買
2019/12/09 74.83% 蒙特利爾銀行資本 →$45 開始承保 →跑贏大盤
2019年05月23日 113.68% 高盛 →$55 假設 →中性
2019年02月20日 - 奧本海默 假設 →性能
2019年02月15日 210.8% 利林克·斯旺 →$80 升級 市場表現優於→
2018年09月25日 210.8% 利林克·斯旺 →$80 開始承保 →市場表現

What is the target price for Agios Pharmaceuticals (AGIO)?

Agios製藥(Agio)的目標價是多少？

The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on August 7, 2023. The analyst firm set a price target for $32.00 expecting AGIO to rise to within 12 months (a possible 24.32% upside). 5 analyst firms have reported ratings in the last year.

納斯達克(Agios PharmPharmticals)的最新目標價是由摩根大通於2023年8月7日報道的。這家分析公司將目標價定為32.00美元，預計Agio將在12個月內上漲(可能上漲24.32%)。去年有5家分析公司公佈了評級。

What is the most recent analyst rating for Agios Pharmaceuticals (AGIO)?

分析師對Agios製藥公司(Agio)的最新評級是多少？

The latest analyst rating for Agios Pharmaceuticals (NASDAQ: AGIO) was provided by JP Morgan, and Agios Pharmaceuticals maintained their neutral rating.

納斯達克(Sequoia Capital：AGIO)的最新分析師評級由摩根大通提供，Agios製藥維持中性評級。

When is the next analyst rating going to be posted or updated for Agios Pharmaceuticals (AGIO)?

Agios PharmPharmticals(Agio)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agios Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agios Pharmaceuticals was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Agios製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Agios製藥的上一次評級是在2023年8月7日提交的，所以你應該預計下一次評級將在2024年8月7日左右的某個時候公佈。

Is the Analyst Rating Agios Pharmaceuticals (AGIO) correct?

分析師對Agios製藥(Agio)的評級正確嗎？

While ratings are subjective and will change, the latest Agios Pharmaceuticals (AGIO) rating was a maintained with a price target of $33.00 to $32.00. The current price Agios Pharmaceuticals (AGIO) is trading at is $25.74, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Agios製藥(Agio)評級維持不變，目標價在33.00美元至32.00美元之間。Agios製藥(Agio)目前的交易價格為25.74美元，超出了分析師的預測區間。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論